← Kiniksa Pharmaceuticals International, plc
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 | $38.5m |
$220.2m
+471.24%
|
$270.3m
+22.74%
|
$423.2m
+56.60%
|
$677.6m
+60.09%
|
$840.8m
+24.10%
|
|
| Cost of Revenue | $804k |
$56.4m
+6909.16%
|
$86.6m
+53.66%
|
$135.0m
+55.90%
|
$112.0m
-17.01%
|
$9.1m
-91.88%
|
$47.0m
+416.11%
|
$89.9m
+91.48%
|
$60.9m
-32.27%
|
$77.7m
+27.52%
|
$382.6m
+392.52%
|
|
| Cost of goods sold | $804k |
$56.4m
+6909.16%
|
$86.6m
+53.66%
|
$135.0m
+55.90%
|
$112.0m
-17.01%
|
$9.1m
-91.88%
|
$47.0m
+416.11%
|
$89.9m
+91.48%
|
$60.9m
-32.27%
|
$77.7m
+27.52%
|
$382.6m
+392.52%
|
|
| Gross Profit (Calculated) (derived) | ($804k) |
($56.4m)
-6909.16%
|
($86.6m)
-53.66%
|
($135.0m)
-55.90%
|
($112.0m)
+17.01%
|
$29.4m
+126.28%
|
$173.2m
+488.28%
|
$180.3m
+4.11%
|
$362.3m
+100.93%
|
$599.9m
+65.57%
|
— | |
| Research and Development Expense | — | $56.4m | $86.6m | $135.0m | $112.0m | $99.3m | $65.5m | $76.1m | $111.6m | $96.9m | $127.1m | |
| General and Administrative Expense | $29k | $9.0m | $21.6m | $35.0m | $45.3m | $85.9m | $98.0m | $129.4m | $168.0m | $196.3m | $39.5m | |
| Operating Expenses | $348k | $65.4m | $108.2m | $170.0m | $157.4m | $195.2m | $210.4m | $295.5m | $468.9m | $600.3m | $740.6m | |
| Operating Income (Loss) | ($833k) |
($65.4m)
-7749.08%
|
($108.2m)
-65.38%
|
($170.0m)
-57.14%
|
($157.4m)
+7.41%
|
($156.6m)
+0.46%
|
$9.8m
+106.24%
|
($25.2m)
-357.81%
|
($45.6m)
-81.04%
|
$77.2m
+269.28%
|
$100.2m
+29.82%
|
|
| Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax | — | — | ($4k) | $37k | ($67k) | ($32k) | $110k | ($38k) | ($169k) | $138k | — | |
| Other income, net | — | — | — | — | $1.1m | $97k | $1.3m | $8.5m | $9.5m | $11.6m | $14.0m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | ($65.4m) | ($105.6m) | ($168.1m) | ($162.0m) | ($164.3m) | ($84.1m) | ($91.1m) | ($7.7m) | $2.8m | $114.3m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | ($64.9m) | ($103.4m) | ($163.9m) | ($156.2m) | ($156.5m) | $11.0m | ($16.7m) | ($36.2m) | $88.9m | $114.3m | |
| Benefit (provision) for income taxes | — | ($2k) | $214k | $2.0m | ($5.2m) | ($1.4m) | $172.3m | $30.7m | ($7.0m) | ($29.9m) | — | |
| Current Income Tax Expense (Benefit) | — | $199k | $764k | $1.1m | $791k | $1.4m | $13.2m | $3.1m | ($1.1m) | $16.9m | $33.6m | |
| Net Income (Loss) Attributable to Parent | ($1.5m) |
($64.9m)
-4139.02%
|
($103.2m)
-59.12%
|
($161.9m)
-56.81%
|
($161.4m)
+0.30%
|
($157.9m)
+2.14%
|
$183.4m
+216.11%
|
$14.1m
-92.32%
|
($43.2m)
-406.68%
|
$59.0m
+236.61%
|
$80.7m
+36.70%
|
|
| Earnings Per Share, Basic | — | — | — | ($2.99) | ($2.61) | ($2.30) | $2.64 | $0.20 | ($0.60) | $0.80 | $1.06 | |
| Earnings Per Share, Diluted | ($0.01) | ($35.85) | ($3.49) | ($2.99) | ($2.61) | ($2.30) | $2.60 | $0.20 | ($0.60) | $0.75 | $0.99 | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | 54.0m | 61.8m | 68.6m | 69.4m | 70.1m | 71.4m | 74.2m | 76.2m | |
| Weighted average ordinary shares outstanding, basic | — | — | — | 54.0m | 61.8m | 68.6m | 69.4m | 70.1m | 71.4m | 74.2m | — | |
| Weighted average ordinary shares outstanding, diluted | — | — | — | 54.0m | 61.8m | 68.6m | 70.4m | 71.9m | 71.4m | 79.0m | — | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 54.0m | 61.8m | 68.6m | 70.4m | 71.9m | 71.4m | 79.0m | 81.9m | |
| Additional Financial Items | ||||||||||||
| Collaboration expenses | — | — | — | — | — | $835k | $24.1m | $56.5m | $128.3m | $229.5m | — | |
| Income (loss) from operations | ($833k) |
($65.4m)
-7749.08%
|
($108.2m)
-65.38%
|
($170.0m)
-57.14%
|
($157.4m)
+7.41%
|
($156.6m)
+0.46%
|
$9.8m
+106.24%
|
($25.2m)
-357.81%
|
($45.6m)
-81.04%
|
$77.2m
+269.28%
|
$100.2m
+29.82%
|
|
| Total other comprehensive income (loss) | — | — | ($4k) | $37k | ($67k) | ($32k) | $110k | ($38k) | ($169k) | $138k | — | |
| Total comprehensive income (loss) | ($1.5m) | ($64.9m) | ($103.2m) | ($161.8m) | ($161.4m) | ($158.0m) | $183.5m | $14.0m | ($43.4m) | $59.1m | — |